Cardiovascular disease and cancer are leading causes of death. Both diseases share the same risk factors and, having the highest incidence and prevalence in the elderly, they often coexist in the same individual. Furthermore, the enhanced survival of cancer patients registered in the last decades and linked to early diagnosis and improvement of care, not infrequently exposes them to the appearance of ominous cardiovascular complications due to the deleterious effects of cancer treatment on the heart and circulatory system. The above considerations have led to the development of a new branch of clinical cardiology based on the principles of multidisciplinary collaboration between cardiologists and oncologists: Cardio-oncology, which aims to find solutions to the prevention, monitoring, diagnosis and treatment of heart damage induced by cancer care in order to pursue, in the individual patient, the best possible care for cancer while minimizing the risk of cardiac toxicity. In this consensus document we provide practical recommendations on how to assess, monitor, treat and supervise the candidate or patient treated with potentially cardiotoxic cancer therapy in order to treat cancer and protect the heart at all stages of the oncological disease. Cardiovascular diseases and cancer often share the same risk factors and can coexist in the same individual. Such possibility is amplified by the deleterious effects of cancer treatment on the heart. The above considerations have led to the development of a new branch of clinical cardiology, based on multidisciplinary collaboration between cardiologist and oncologist: the cardio-oncology. It aims to prevent, monitor, and treat heart damages induced by cancer therapies in order to achieve the most effective cancer treatment, while minimizing the risk of cardiac toxicity. In this paper, we provide practical recommendations on how to assess, monitor, treat and supervise patients treated with potential cardiotoxic cancer therapies.
Introduction
Cardiovascular (CV) disease and cancer are the cause of about two-thirds of all deaths worldwide. 1 Due to the progressive aging of the population the eventuality that a same individual may be affected by both, CV and cancer, is not uncommon. 2 The association, indeed, is not casual, cancer and heart diseases may share the same risk factors, 3 and such chance is amplified by cardiovascular complication of oncologic therapy that can lead to premature morbidity and death of cancer survivors. 4 The above considerations have led to the development of a new branch of clinical cardiology: the cardio-oncology, 5 a discipline based on the collaboration among cardiologists, oncologists and other medical specialists in order to find solutions for the prevention, monitoring, diagnosis and treatment of heart damage before, during and after antitumour treatments ( Figure 1) . In this Executive Summary we point out the major key points in order to achieve the most effective cancer treatment, while minimizing the risk of cardiac toxicity.
The assessment of the cardiovascular risk
Many oncologic drugs have cardiotoxic effects 4 ( Table 1 ) often exacerbated by the presence of a pre-existing heart disease (clinical or subclinical) or by the presence of traditional CV risk factors. 4 The estimation of CV risk profile of patients ( Table 2 ) is valuable in cardio-oncology and should be integrated with data related to tumour treatment, in order to improve the choice on the most appropriate chemotherapy protocol and on the best cardio-protective therapy as well as to perform the most appropriate monitoring measures to schedule the follow-up. The CV risk factors should be treated with appropriate primary and secondary prevention measures according with the most recent guidelines on cardiovascular prevention of the European Society of Cardiology (ESC). 6 
Figure 1
The collaborative model in cardio-oncology. The realization of a management strategy to effectively treat cancer and minimize the risk of cardiac damage provides for close multidisciplinary collaboration between the different actors involved in patient management. The cooperation is particularly necessary in the presence of a patient with a structural heart disease or a high CV risk and with potentially cardiotoxic care plan.
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*, Selected examples on the frequency of use of the drug; þþþ, >10%; þþ, 1-10%; þ, <1% or rare; , observed but the precise incidence has not been well established; -, complication not reported; CML, chronic myeloid leukemia; GIST, gastrointestinal stromal tumour; HCC, hepatocellular carcinoma; Emat., haematological; HF, heart failure; HNC, cancer of the head and neck; RCC, carcinoma of the kidney; TKI, tyrosine kinase inhibitor.
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Heart failure
Heart failure (HF) is a very common complication of antineoplastic treatments and may occur with several classes of anticancer drugs 7-9 ( Table 1) . Table 3 shows the risk factors for anthracyclines cardiotoxicity that may lead also to late onset cardiomyopathy. 10, 11 Other conventional chemotherapies, cyclophosphamide, cisplatin, ifosfamide, and taxanes (paclitaxel and docetaxel), can rarely induce left ventricular dysfunction (LVD) and HF. Immunotherapies and targeted therapies ( Table 1 ) can, also, cause LVD and HF. Moreover, concomitant use of anthracyclines with trastuzumab, a monoclonal antibody directed against the receptor HER2/ErbB2, especially in cancer patients with high CV risk, may lead to severe cardiotoxicity effects. [7] [8] [9] 12, 13 Nevertheless, trastuzumab-related cardiomyopathy is not dependent on cumulative dose and is considered to be reversible upon treatment discontinuation and proper therapy. 9 The cardiotoxicity risk of other anti-HER2/ErbB2 targeted agents (lapatinib, pertuzumab, and trastuzumabemtansine) appears to be similar to that of trastuzumab. 9 Vascular endothelial growth factor (VEGF) inhibitors can cause reversible or irreversible cardiac side effects: arterial hypertension is the most frequent, with potential LVD and HF.
Management
Cardiotoxic cardiomyopathy is difficult to treat and has a relatively poor prognosis if not promptly diagnosed.
14 Among the imaging techniques, a predominant role is played by echocardiography, a non-invasive, repeatable, available and relatively inexpensive technique. 9 The ejection fraction (EF) is the echocardiographic parameter most frequently used to monitor heart health. Significant declines of EF often may occur at a later time with irreversible cardiac damage. One of the aims of clinical research is to find the best technique able to identify the early cardiac damage before it produces alterations of the common ventricular contractility indexes, and then before the cardiac damage becomes irreversible ( Table 4 ). In the recent years, Global Longitudinal Strain (GLS) technique, assessed using automated speckle-tracking echocardiography (STE), has emerged for detecting and quantifying LVD. A drop of 10% from baseline is very largely abnormal and may represent subclinical dysfunction in order to consider cardioprotection also in patients without the classic criteria of cardiotoxicity (LVEF < 50%).It has been largely demonstrated that this technique is very promising to monitor the effects of cardioprotection.
Biomarkers (Table 5) , also, may be used as 'red flags' to encourage a close clinical and instrumental monitoring and treatment. The same biomarker assay may be used for continued screening throughout the treatment pathway and substantial increases during follow-up may anticipate asymptomatic LVD in high CV risk patient treated with potentially cardiotoxic chemotherapy. Nevertheless at present the evidence to establish the interpretation of subtle variation is insufficient and their role as exclusive Consensus document on clinical and management pathways of cardio-oncology D373 
Strategies for reducing cardiotoxicity
In the absence of definite treatments that can reverse the anthracyclines-related myocardial damage, it is important to identify new treatment strategies that prevent or minimize the potential cardiotoxic side effects (Table 6) , especially in high risk patients ( Table 3 ) that require a strict control of traditional CV risk factor.
Ischaemic heart disease
Radiation therapy as well as many cancer drugs can induce myocardial ischaemia 4, 7, 9 ( Tables 1 and 7) .
Fluoropyrimidine and capecitabine
Asymptomatic ST-segment changes on ECG represents the most frequent cardiotoxic manifestation (55%). Chest pain with or without ST-segment changes is the common clinical complaint (45%) and evolution in acute coronary syndrome may occur. Patients should be closely monitored for myocardial ischaemia using regular ECG. The symptoms usually occur within the first 72 h of 5-fluorouracil (5-FU) infusion and in the first 6 days of initiation in the case of oral administration of capecitabine. 15 Occasionally, 5-FU and Capecitabine toxicity appear as acute heart failure and Tako-tsubo syndrome with LVD, in such case ventricular arrhythmias and sudden death may occur. Ischaemic heart disease can also be a complication of antiangiogenic agents: bevacizumab and tyrosine kinase inhibitors (sunitinib, sorafenib, ponatinib, axitinib, pazopanib, regorafenib). 9 Coronary artery disease may be a late complication of high radiation doses to mediastinum.
Management
In the case of fluoropyrimidine toxicity, chemotherapy should be stopped and patients hospitalized in coronary intensive care if acute coronary syndrome is suspected. The administration of non-dihydropyridine calcium channel blockers (verapamil or diltiazem) and nitrates may be indicated for the frequent occurrence of coronary spasm. If there is an absolute indication on drug rechallenge, the treatment should be performed with half dose and the patients monitored closely. The association of calcium channel blockers therapy may be useful.
Arrhythmias
In cancer patients Heart Rhythm Disturbances (HRD) may be the result of multiple risk factors. Metabolic disorders, electrolyte disturbances, medications (e.g. antihistamines, antiemetic, anti-infective, psychotropic drugs) can affect the appearance of cardiac arrhythmias. Nevertheless, HRD are more frequent with some chemotherapies (Tables 1 and 8) . A 12-lead ECG should be recorded and the QT interval, corrected for heart rate with Bazett's or Fridericia's formula, should be obtained in all patients at baseline. Treatment should be interrupted or alternative regimens considered if the QTc is >500 ms, QTc prolongation is >60 ms or arrhythmias are present. Factors as hypokalaemia, hypomagnesiemia, extreme bradycardia, and QT-prolonging drugs should be minimized inpatients treated with potential QT-prolonging chemotherapy (Figure 2 ). 
Arterial hypertension
Hypertension is a frequent co-morbidity in patients with cancer and may be worsened or newly induced by steroids o non-steroid anti inflammatory drugs frequently used in oncology. Antiangiogenetic agents ( Table 1) can induce hypertension and degenerate to related heart complications (i.e. heart failure, myocardial ischaemia). ACE inhibitors or ARBs, beta-blockers and dihydropyridine calcium channel blockers are the antihypertensive drugs of choice. Non-dihydropyridine calcium channel blockers should preferably be avoided due to drug interactions.
Thrombo-embolic disease
Thrombo-embolism often complicates the course of cancer and recognizes different aetiological moments ( Table 9 ). The arterial thrombotic events (ETA) in cancer can occur in case of treatment with anti-angiogenic drugs, cisplatin, VEGF inhibitors, and hormonal therapies. Ischaemia/myocardial infarction is the most common clinical manifestation. The pro-thrombotic state may facilitate embolic events secondary to atrial fibrillation. The most frequent thrombo-embolic complications in cancer patients are venous thrombo-embolism (VTE) with deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE is the second cause of death in cancer patients. It may affect up to 20% of hospitalized patients and is frequently undiagnosed. A four weeks antithrombotic therapy with low molecular weight heparin (LMWH) is currently recommended for VTE prophylaxis by consensus guidelines. 9 In the case of major surgery, systematic prophylaxis for VTE in outpatient admitted for chemotherapy is not recommended and the decision should be individualized. In stable patients LMWH given over a period of 3-6 months is the first choice for TVE therapy in cancer patients. At the moment we do not have enough data to support the use of fondaparinux or new oral anticoagulants (NOAC) for the initial treatment of acute VTE in patients with cancer. We are waiting the results of Hokusai VTE-cancer to know if edoxaban is similar to dalteparin in preventing recurrence of acute VTE following and initial index in cancer subjects. 15 Different NOACs may differ because of potential drug interactions and sensitivity to renal or hepatic dysfunction. The use of vitamin K antagonists (VKA) in cancer patients is complicated; difficulties in maintaining a therapeutic International Normalised Ratio (INR) occur due to a variety of reasons such as drug interactions, unpredictable bioavailability, vomiting, malnutrition or diarrhea, poor compliance for repeated laboratory tests.
Surveillance in the follow-up
Cancer patients follow-up is critical for the prevention and treatment of possible late cardiovascular complications (Table 10) .
Cancer patients should be aware on the possible cardiovascular risk factors, overall subjects treated with anthracyclines or mediastinal radiotherapy. At 10 years it is mandatory to perform stress test or CT coronary angiography 16 ( Figure 3 ). Moreover, patients should be encouraged to a healthy lifestyle. A careful surveillance is often necessary for the patients in long-term hormonal therapy. Tamoxifen may increase the risk of thromboembolic complications and aromatase inhibitors have been linked to increased risk of heart disease The same applies to patients treated with androgen deprivation therapy (ADT) for prostate cancer which are prone to metabolic syndrome, diabetes, accelerated atherosclerosis, and cardiovascular events. 
